We are live on ! Find out more
GAMA

Graticule Asia Macro Advisors Portfolio holdings

AUM $649M
This Fund
S&P 500
This Quarter Est. Return
+9.33%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.1B
AUM Growth
+$387M
Cap. Flow
+$328M
Cap. Flow %
15.58%
Top 10 Hldgs %
54.48%
Holding
178
New
57
Increased
17
Reduced
32
Closed
68

Top Buys

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$110M
2
AMZN icon
Amazon
AMZN
+$40.8M
3
V icon
Visa
V
+$33.1M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$30.9M
5
EA icon
Electronic Arts
EA
+$24.4M

Top Sells

Rank Stock Value
1
INDA icon
iShares MSCI India ETF
INDA
+$38.1M
2
XYZ
Block Inc
XYZ
+$36.6M
3
CSCO icon
Cisco
CSCO
+$28.7M
4
JD icon
JD.com
JD
+$27.7M
5
LUV icon
Southwest Airlines
LUV
+$24.8M

Sector Composition

Rank Sector Weight
1 Communication Services 10.2%
2 Technology 9.11%
3 Consumer Discretionary 5.4%
4 Financials 4%
5 Healthcare 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EPZM
101
DELISTED
Epizyme, Inc
EPZM
$1.08M 0.05%
+71,460
New +$1.08M
HUM icon
102
Humana
HUM
$46.7B
$1.03M 0.05%
4,275
-5,625
-57% -$1.27M
TGS icon
103
Transportadora de Gas del Sur
TGS
$4.59B
$989K 0.05%
+61,846
New +$933K
AERI
104
DELISTED
Aerie Pharmaceuticals
AERI
$594K 0.03%
11,300
+2,480
+28% +$115K
ACHN
105
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$574K 0.03%
+125,000
New +$502K
RGNX icon
106
Regenxbio
RGNX
$623M
$487K 0.02%
24,680
-24,470
-50% -$474K
PTGX icon
107
Protagonist Therapeutics
PTGX
$8.75B
$328K 0.02%
29,027
-2,800
-9% -$29.9K
CALA
108
DELISTED
Calithera Biosciences, Inc
CALA
$303K 0.01%
1,020
-3,858
-79% -$1.03M
RCKT icon
109
Rocket Pharmaceuticals
RCKT
$348M
$31K ﹤0.01%
4,054
ADBE icon
110
Adobe
ADBE
$89.5B
-46,000
Closed -$5.99M
ALK icon
111
Alaska Air
ALK
$5.15B
-254,150
Closed -$23.4M
ALNY icon
112
Alnylam Pharmaceuticals
ALNY
$36.3B
-18,018
Closed -$923K
BA icon
113
CALL
Boeing
BA
$165B
-370,000
Closed -$65.4M
BABA icon
114
Alibaba
BABA
$269B
-2,739
Closed -$338K
BIIB icon
115
Biogen
BIIB
$29.9B
-24,795
Closed -$6.78M
BMRN icon
116
BioMarin Pharmaceuticals
BMRN
$11.5B
-24,060
Closed -$2.11M
BP icon
117
BP
BP
$113B
-338,296
Closed -$10.2M
CHTR icon
118
Charter Communications
CHTR
$14.7B
-63,816
Closed -$20.9M
CPRT icon
119
Copart
CPRT
$25.9B
-701,600
Closed -$5.43M
CSCO icon
120
Cisco
CSCO
$450B
-881,000
Closed -$28.7M
CSTM icon
121
Constellium
CSTM
$3.96B
-370,000
Closed -$2.4M
CVX icon
122
PUT
Chevron
CVX
$388B
-270,000
Closed -$29M
DAL icon
123
Delta Air Lines
DAL
$55.9B
-136,500
Closed -$6.69M
DIS icon
124
Walt Disney
DIS
$165B
-145,300
Closed -$16.5M
EDIT icon
125
Editas Medicine
EDIT
$399M
-50,000
Closed -$1.12M

Similar funds

Graticule Asia Macro Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Graticule Asia Macro Advisors held 178 positions worth $2.1B, up 23% from $1.72B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Graticule Asia Macro Advisors deployed $328M of net new capital in Q2 2017, opening 57 new positions and adding to 17 existing holdings. Its largest new stake was Electronic Arts: 237,000 shares worth $25.1M.

By sector, the portfolio is most concentrated in Communication Services at 10% of assets, down from 12% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Block Inc, an estimated $36.6M trimmed.

  • Graticule Asia Macro Advisors's largest Q2 2017 buy was Electronic Arts: 237,000 shares worth $25.1M.
  • Graticule Asia Macro Advisors added most to Activision Blizzard in Q2 2017, an estimated $110M increase.
  • Graticule Asia Macro Advisors's biggest Q2 2017 reduction was Block Inc, cutting an estimated $36.6M.
  • Graticule Asia Macro Advisors fully exited iShares MSCI India ETF in Q2 2017, selling an estimated $38.1M.
  • Graticule Asia Macro Advisors's ten largest holdings make up 54% of its $2.1B portfolio in Q2 2017.
  • Graticule Asia Macro Advisors opened 57 new positions and closed 68 in Q2 2017.
  • Graticule Asia Macro Advisors's portfolio value rose 23% quarter-over-quarter to $2.1B.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.